2nd Circ. Questions Takeda's 'Lazarus' Take On Drug Patents

Law360 (April 7, 2021, 6:53 PM EDT) -- A Second Circuit panel grilled Takeda in oral arguments Wednesday on the pharmaceutical company's bid to duck antitrust claims that it delayed the entry of generic alternatives to diabetes treatment Actos, with one judge likening the company's exclusivity claim to resurrecting "Lazarus from the dead."

At stake are U.S. District Judge Ronnie Abrams' rulings, which preserved antitrust claims brought by two groups of Actos buyers that say Takeda falsely told the U.S. Food and Drug Administration that two new patents describing how to combine the drug with others covered its chemical ingredients — rather than simply methods of using the drug...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!